VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Rhea-AI Summary
Valion Bio (Nasdaq: VBIO) reported first quarter 2026 results and business updates, its first full quarter under the new identity and with Velocity Bioworks integrated.
Operating expenses were $5.6M and net loss was $6.2M, with $7.2M in cash. Entolimod and Entolasta development, U.S. government engagement, and Velocity Bioworks CDMO integration advanced.
AI-generated analysis. Not financial advice.
Positive
- First full quarter operating as focused clinical-stage immunotherapeutics platform
- Velocity Bioworks CDMO integration supporting internal manufacturing and third-party business development
- Broader U.S. government engagement on Entolimod with BARDA, NIAID, and Department of War
- Entolimod supported by FDA Fast Track and Orphan Drug designations and Animal Rule pathway
- Previously demonstrated 200-fold manufacturing scale-up to ~1.3 million human doses at 50-liter fermentation
- Velocity Bioworks expected to provide stand-alone CDMO revenue and operating leverage
Negative
- Operating expenses rose to $5.6M from $1.4M year over year
- Net loss increased to $6.2M from $1.5M year over year
- Cash and cash equivalents declined to $7.2M from $12.6M at year-end 2025
- Company is evaluating capital alternatives to fund pipeline, regulatory, and manufacturing milestones
News Market Reaction – VBIO
On the day this news was published, VBIO declined 5.47%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.4% during that session. Argus tracked a trough of -16.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $196K from the company's valuation, bringing the market cap to $3.39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks in the provided biotechnology sector list showed concurrent momentum, suggesting the -12% move and below-average volume are company-specific rather than part of a sector-wide shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings date notice | Neutral | +15.6% | Announcement of Q1 2026 reporting date and conference call logistics. |
| May 6 | Facility opening | Positive | +2.0% | Grand opening of Velocity Bioworks domestic biomanufacturing facility. |
| May 5 | Clinical funding | Positive | -3.4% | NIAID to fully fund up to $7M of BLA‑enabling in vivo studies. |
| May 4 | Executive hire | Neutral | -3.4% | Appointment of General Counsel to support regulatory and capital initiatives. |
Recent company news often produced modest moves, with both positive and negative reactions; one key clinical funding update saw a negative reaction, indicating occasional divergence between perceived positives and price.
Over the past weeks, Valion Bio has focused on building its Entolimod platform and manufacturing base. On May 5, 2026, NIAID committed up to $7 million for BLA‑enabling studies, followed by the May 6, 2026 opening of the Velocity Bioworks facility in San Antonio. A new General Counsel was appointed on May 4, 2026. An earnings-date announcement on May 11, 2026 prompted a strong positive move, while today’s Q1 2026 results highlight higher operating costs and deeper investment in the transformed business model.
Market Pulse Summary
The stock moved -5.5% in the session following this news. A negative reaction despite detailed strategic commentary fits a backdrop of sharply higher expenses and a wider quarterly loss. Operating expenses rose to $5.6 million and net loss reached $6.2 million, while cash declined to $7.2 million. The market could have focused on the capital needs implied by these figures, even as the company emphasized government engagement, Velocity Bioworks integration, and the Entolimod/Entolasta pipeline as longer-term value drivers.
Key Terms
acute radiation syndrome medical
animal rule regulatory
fast track regulatory
orphan drug regulatory
cdmo technical
oncology supportive care medical
neutropenia medical
immunosenescence medical
AI-generated analysis. Not financial advice.
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity Bioworks
Conference Call to be Held Today at 1:30 PM PT / 4:30 PM ET
First Quarter 2026 Highlights and Subsequent Events
- Completed corporate transformation, including the change of the company's legal name from Tivic Health Systems, Inc. to Valion Bio, Inc. and the change of the company's Nasdaq listing symbol from TIVC to VBIO, consolidating the company's identity as a focused clinical-stage immunotherapeutics platform.
- Advanced engagement with
U.S. government agencies, including BARDA, the National Institute of Allergy and Infectious Diseases (NIAID), and the Department of War, regarding the development, procurement, and stockpiling of Entolimod as a medical countermeasure for Acute Radiation Syndrome (ARS).
- Continued integration of Velocity Bioworks, the company's wholly owned contract development and manufacturing organization (CDMO) subsidiary acquired in December 2025, with operational workstreams advancing across both internal pipeline manufacturing support and third-party CDMO business development.
- Reinforced regulatory pathway for Entolimod under the FDA's Animal Rule, supported by the program's Fast Track and Orphan Drug designations and the previously demonstrated 200-fold manufacturing scale-up at 50-liter fermentation, equivalent to approximately 1.3 million human doses.
- Continued advancement of Entolasta, the company's next-generation TLR5 agonist, designed to support broader therapeutic applications including oncology supportive care, longevity, and immunosenescence.
- Maintained domestic biologics manufacturing footprint through Velocity Bioworks'
San Antonio, Texas operations, addressing both the company's internal pipeline manufacturing requirements and a structurally underserved Phase I and Phase II domestic biologics manufacturing market.
The first quarter of 2026 was, by design, a quarter of execution rather than announcement: the first full quarter operating with Velocity Bioworks integrated, the first quarter following the previously demonstrated 200-fold manufacturing scale-up, and the first quarter under the Valion Bio identity. The transition follows the divestiture and discontinuation of the legacy consumer bioelectronics business completed in 2025 and consolidates the company's focus on the development and potential commercialization of its TLR5 platform.
"The transition to Valion Bio is more than a change of name and ticker. It reflects the institutional identity we have built — a clinical-stage immunotherapeutics company anchored by a differentiated TLR5 platform, an in-house biologics manufacturing capability through Velocity Bioworks, and increasing visibility within the federal agencies responsible for national medical countermeasure preparedness," said Michael K. Handley, Chief Executive Officer of Valion Bio. "Each of those pillars advanced through the first quarter, and we believe the company enters the balance of 2026 with sharper focus, deeper engagement, and broader optionality than at any point in our history."
Government engagement broadened across multiple agencies during the quarter. Building on the previously disclosed non-clinical evaluation agreement with NIAID, Valion Bio further advanced Entolimod toward potential procurement and stockpiling under the FDA's Animal Rule pathway. Engagement with BARDA, the Department of War, and additional federal stakeholders progressed in scope and depth over the same period. Entolimod's profile — dual gastrointestinal and hematopoietic protection, repeat-dose tolerability supported by a deletion-variant design that reduces immunogenicity, Fast Track and Orphan Drug designations, and a domestic manufacturing footprint — represents a meaningful point of differentiation from currently fielded countermeasures, and one that aligns with both Strategic National Stockpile modernization priorities and allied-government preparedness initiatives.
Integration of Velocity Bioworks advanced on multiple fronts during the quarter. The
"Beyond Entolimod's role in radiation defense, the most significant commercial opportunity in front of us is oncology supportive care," Mr. Handley continued. "Neutropenia and related conditions affect a meaningful proportion of patients undergoing chemotherapy and radiation therapy, and the mechanistic profile of Entolimod — together with the broader applicability of our second-generation molecule, Entolasta — positions us to address that market with a differentiated entry. Velocity Bioworks accelerates our path on both fronts: it compresses our internal development timelines, structurally lowers our manufacturing cost base, and creates a stand-alone CDMO revenue stream serving the broader biotech industry. The first quarter was a quarter of execution, and we are building."
Pipeline development advanced across both molecules during the quarter. Entolimod continued progressing toward potential approval under the FDA's Animal Rule, with regulatory and clinical development workstreams positioned to support both medical countermeasure and oncology supportive care applications, including neutropenia. Entolasta, the company's next-generation TLR5 agonist, continued to advance as a strategic platform extension — engineered to support broader therapeutic applications including longevity, immunosenescence, and additional oncology supportive care indications, areas where the underlying TLR5 mechanism is mechanistically suited and the addressable markets are substantial.
Financial Results for the Three Months Ended March 31, 2026
Operating expenses for the three months ended March 31, 2026 were
Net loss for the three months ended March 31, 2026 was
Conference Call and Webcast Information
Valion Bio will host a conference call and webcast today, Thursday, May 14, 2026, at 1:30 PM PT / 4:30 PM ET to discuss the company's first quarter 2026 financial results and provide a business update. The webcast may be accessed at https://www.webcaster5.com/Webcast/Page/2865/54024. Participants may access the call by dialing 888-506-0062 (
About Entolimod for Acute Radiation Syndrome
Entolimod (CBLB502) is a recombinant deletion variant of Salmonella FliC flagellin engineered to activate TLR5 selectively. Upon engagement, Entolimod triggers NF-κB-dependent signaling to stimulate G-CSF, PI3K, and IL-6 production, promote multi-tissue cytoprotection, and inhibit apoptosis in radiosensitive hematopoietic and gastrointestinal tissues. The compound has demonstrated survival benefit as both a radioprotectant and a radiomitigant in controlled non-human primate studies under the FDA's Animal Rule.
About Valion Bio, Inc.
Valion Bio, Inc. (Nasdaq: VBIO), the new corporate identity of Tivic Health Systems, Inc., is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease, and immune dysregulation. The Company's lead candidate, Entolimod for acute radiation syndrome (ARS), has been extensively studied and has demonstrated survival benefits and improved tissue recovery in animal models under the FDA's Animal Rule. Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling pathways to protect cells from damage and stimulate immune responses. Entolimod for ARS has received Fast Track and Orphan Drug designations from the
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other
Investor and Media Contact:
Rich Cockrell
CG Capital
vbio@cg.capital
www.cg.capital
Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) Condensed Consolidated Balance Sheets (in thousands, except share and per share data) | ||||
March 31, 2026 | December 31, | |||
(Unaudited) | (Audited) | |||
ASSETS | ||||
Cash and cash equivalents | $ 7,215 | $ 12,645 | ||
Other current assets | 1,437 | 361 | ||
TOTAL CURRENT ASSETS | 8,652 | 13,006 | ||
PROPERTY AND EQUIPMENT, NET | 12,644 | 12,641 | ||
ROU ASSETS | 10,086 | — | ||
GOODWILL | 3,457 | 3,457 | ||
OTHER NON-CURRENT ASSETS | 3,376 | 2,503 | ||
TOTAL ASSETS | $ 38,215 | $ 31,607 | ||
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY | ||||
Accounts payable and accrued expenses | $ 2,119 | $ 640 | ||
Operating lease liabilities, current | $ 492 | $ — | ||
Other current liabilities | $ 4 | $ 6 | ||
TOTAL CURRENT LIABILITIES | 2,615 | 646 | ||
DEBT, NET | 6,899 | 6,454 | ||
OPERATING LEASE LIABILITIES | 9,643 | — | ||
OTHER NON-CURRENT LIABILITIES | 510 | 340 | ||
TOTAL NON-CURRENT LIABILITIES | 17,052 | 6,794 | ||
TEMPORARY EQUITY | 7,486 | 7,370 | ||
STOCKHOLDERS' EQUITY | ||||
Common stock | 2 | 2 | ||
Additional paid in capital | 70,094 | 69,392 | ||
Accumulated deficit | (59,034) | (52,597) | ||
TOTAL STOCKHOLDERS' EQUITY | 11,062 | 16,797 | ||
TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY | $ 38,215 | $ 31,607 | ||
Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) Condensed Consolidated Statements of Operations (in thousands, except share and per share data) | ||||
Three Months Ended March 31, | ||||
2026 | 2025 | |||
OPERATING EXPENSES | ||||
Research and development | $ 1,854 | $ 335 | ||
Selling, general and administrative | 3,780 | 1,042 | ||
TOTAL OPERATING EXPENSES | 5,634 | 1,377 | ||
NET OPERATING LOSS | (5,634) | (1,377) | ||
OTHER INCOME (EXPENSE), NET | (591) | 4 | ||
NET LOSS BEFORE DISCONTINUED OPERATIONS | (6,225) | (1,373) | ||
INCOME (LOSS ) FROM DISCONTINUED OPERATIONS | 23 | (129) | ||
NET LOSS | $ (6,202) | $ (1,502) | ||
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED | $ (2.23) | $ (2.52) | ||
WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED | 2,883,650 | 569,368 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-reports-first-quarter-2026-financial-results-302772859.html
SOURCE Valion Bio, Inc.